Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)
✉ Email this page to a colleague
AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)
| Docket | ⤷ Try a Trial | Date Filed | 2014-06-02 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
| Jury Demand | None | Referred To | |
| Patents | 6,395,767; 7,951,400; 8,628,799; RE44,186 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Mylan Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-06-02 | 1 | Method.” The RE’186 patent is a reissue of U.S. Patent No. 6,395,767 (“the ’767 patent”), which issued on…RE44,186 (“the RE’186 patent”) and U.S. Patent No. 7,951,400 (“the ’400 patent”). 3. …expiration of the RE’186 patent and U.S. Patent No. 8,628,799 (“the ’799 patent”). … This is an action for patent infringement arising under the patent laws of the United States, … PATENTS-IN-SUIT 13. On April 30, 2013, the U.S. Patent and Trademark Office | External link to document | |
| 2014-09-23 | 21 | than April 30, 2014. Date of Expiration of Patent: 7,951,400 (November 30, 2028); RE44,186 (July 31, 2023… Date of Expiration of Patent: 7,951,400 (November 30, 2028) … Amended Supplemental information for patent cases involving an Abbreviated New Drug Application… AMENDED SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG… 2 June 2014 1:14-cv-00696-GMS Patent None District Court, D. Delaware | External link to document | |
| 2014-11-05 | 26 | 2014, alleging patent infringement of U.S. Patent Nos. 7,951,400 ("the '400 Patent"), RE44,186…expiration of the '400 Patent, the '186 Patent, and the '799 Patent. (Id. iii! 1-3.) …RE44,186 ("the '186 Patent"), and 8,628,799 ("the '799 Patent"). (D.I. 1.) The … for a drug with patent protection triggered a statutory cause of action for patent holders. 8 Thus, … claimed in a patent or the use of which is claimed in a patent ... if the purpose | External link to document | |
| 2014-06-02 | 3 | Date of Expiration of Patent: 7,951,400 (November 30, 2028) … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: 4/30/14. Date of Expiration of Patent: 11/30/28, 7/31/23, 7/13/25.Thirty Month Stay Deadline… X SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG… 2 June 2014 1:14-cv-00696-GMS Patent None District Court, D. Delaware | External link to document | |
| 2014-06-02 | 4 | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE44,186; 7,951,400; 8,628,799;. (… 2 June 2014 1:14-cv-00696-GMS Patent None District Court, D. Delaware | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
